Maiwei Bio-B (02493): The clinical trial application for 9MW5211 injection has been approved by the National Medical Products Administration.

Zhtng Cijng APP news, Miwi Shngw-B (02493) issued an announcement. Recently, the company received the "Notice of Approval for Clinical Trial of Drugs" issued by the National Medical Products Administration. The clinical trial application for 9MW5211 injection for the indication of multiple sclerosis (MS) has been approved. In addition, its clinical trial application for the indication of inflammatory bowel disease (IBD) has been approved by the National Medical Products Administration and FDA. The company is also actively advancing the clinical trial application work for several other indications, some of which have been accepted by the National Medical Products Administration.